Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients.

Beguin, Yves

Article (Scientific journals)

Beguin, Yves

2002 • In Haematologica, 87 (11), p. 1209-21

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/6306

PubMed
12414352

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Predict6.Amgen.Haematologica.pdf

Publisher postprint (206.25 kB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Algorithms; Anemia/drug therapy/etiology; Data Collection; Dose-Response Relationship, Drug; Erythropoietin, Recombinant/therapeutic use; Humans; Neoplasms/complications/drug therapy; Prognosis; Treatment Outcome

Abstract :

[en] BACKGROUND AND OBJECTIVES: The majority of cancer patients suffer from chronic anemia. While recombinant human erythropoietin (rHuEPO) offers many of the advantages of blood transfusions, response rates to this treatment are variable and in some trials a large proportion of patients (30 50%) did not respond. This failure may be due to factors related to the underlying disease, the chemotherapy given or functional iron deficiency. An accurate means of predicting response to rHuEPO would be beneficial to both healthcare providers and patients. EVIDENCE AND INFORMATION SOURCES: Data were identified by searches of the published literature, including PubMed, references from relevant reviews, and abstracts presented at recent international oncology and hematology meetings. Only papers in English published between 1990 and 2002 were included. References were selected according to direct relevance to the topic discussed and availability. STATE OF THE ART: The best algorithms for predicting response appear to be those combining an assessment of the adequacy of endogenous erythropoietin production together with some early indicators of erythropoietic marrow response. Further characterization of the dose-response relationship of erythropoietic agents may allow better understanding of ways in which response may be enhanced. Adequate iron availability could also contribute to better response rates. PERSPECTIVES: Further characterization of the predictors of response for current and upcoming erythropoietic agents may enhance the management of anemia associated with cancer, and provide more convenient, effective, and flexible therapy.

Disciplines :

Hematology

Author, co-author :

Beguin, Yves ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

Language :

English

Title :

Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients.

Publication date :

2002

Journal title :

Haematologica

ISSN :

0390-6078

eISSN :

1592-8721

Publisher :

Ferrata Storti Foundation, Pavia, Italy

Volume :

Issue :

Pages :

1209-21

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 16 February 2009

Statistics

Number of views

74 (0 by ULiège)

Number of downloads

126 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Johnston E, Crawford J. The hematologic support of the cancer patient. In: Berger A, Portenoy RK, Weissman DE, editors. Principles and Practices of Supportive Oncology. Philadelphia: Lippincott-Raven Publishers; 1998. p. 549-69.
Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: Incidence and treatment. J Natl Cancer Inst 1999; 91:1616-34.
Ludwig H, Fritz E. Anemia in cancer patients. Semin Oncol 1998; 25:2-6.
Sears DA. Anemia of chronic disease. Med Clin North Am 1992; 76:567-79.
Mercadante S, Gebbia V, Marrazzo A, Filosto S. Anaemia in cancer: Pathophysiology and treatment. Cancer Treat Rev 2000; 26:303-11.
Beguin Y. Prediction of response to optimize outcome of treatment with erythropoietin. Semin Oncol 1998; 25:27-34.
Doweiko JP, Goldberg MA. Erythropoietin therapy in cancer patients. Oncology (Huntingt) 1991; 5:43-4.
Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience. J Clin Oncol 1991; 9:1618-26.
Thatcher N, De Campos ES, Bell DR, Steward WP, Varghese G, Morant R, et al. Epoetin α prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. Br J Cancer 1999; 80:396-402.
Del Mastro L, Venturini M, Lionetto R, Garrone O, Melioli G, Pasquetti W, et al. Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol 1997; 15:2715-21.
Dunphy FR, Dunleavy TL, Harrison BR, Boyd JH, Varvares MA, Dunphy CH, et al. Erythropoietin reduces anemia and transfusions after chemotherapy with paclitaxel and carboplatin. Cancer 1997; 79:1623-8.
Harrison LB, Shasha D, White C, Ramdeen B. Radiotherapy-associated anemia: The scope of the problem. The Oncologist 2000; 5:1-7.
Barrett-Lee PJ, Bailey NP, O'Brien MER, Wager E. Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br J Cancer 2000; 82:93-7.
Ortega A, Dranitsaris G, Puodziunas A. A clinical and economic evaluation of red blood cell transfusions in patients receiving cancer chemotherapy. Int J Technol Assess Health Care 1998; 14:788-98.
Estrin JT, Schocket L, Kregenow R, Henry DH. A retrospective review of blood transfusions in cancer patients with anemia. The Oncologist 1999; 4:318-24.
Coiffier B, Guastalla JP, Pujade-Lauraine E, Bastit P. Predicting cancer-associated anaemia in patients receiving non-platinum chemotherapy: Results of a retrospective survey. Eur J Cancer 2001; 37:1617-23.
Ray-Coquard I, Le Cesne A, Rubio MT, Mermet J, Maugard C, Ravaud A, et al. Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. The Elypse 1 Study Group. J Clin Oncol 1999; 17:2840-6.
Hensley ML, Lebeau D, Leon LF, Venkatraman E, Waltzman R, Sabbatini P, et al. Identification of risk factors for requiring transfusion during front-line chemotherapy for ovarian cancer. Gynecol Oncol 2001; 81:485-9.
Pivot X, Guardiola E, Etienne M, Thyss A, Foa C, Otto J, et al. An analysis of potential factors allowing an individual prediction of cisplatin-induced anaemia. Eur J Cancer 2000; 36:852-7.
Skillings JR, Sridhar FG, Wong C, Paddock L. The frequency of red cell transfusion for anemia in patients receiving chemotherapy. A retrospective cohort study. Am J Clin Oncol 1993; 16:22-5.
Koeller JM. Clinical guidelines for the treatment of cancer-related anemia. Pharmacotherapy 1998; 18:156-69.
Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin α is independent of disease response or tumor type: Results from a prospective community oncology study. J Clin Oncol 1998; 16:3412-25.
Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine. First of two parts: Blood transfusion. N Engl J Med 1999; 340:438-47.
Beguin Y. Erythropoietin and the anemia of cancer. Acta Clin Belg 1996; 51:36-52.
Oster W, Herrmann F, Gamm H, Zeile G, Lindemann A, Muller G, et al. Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration. J Clin Oncol 1990; 8:956-62.
Ludwig H, Sundal E, Pecherstorfer M, Leitgeb C, Bauernhofer T, Beinhauer A, et al. Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy. Cancer 1995; 76:2319-29.
Littlewood TJ, Bajetta E, Nortier J, Vercammen E, Rapoport B. Effects of epoetin α on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind placebo-controlled trial. J Clin Oncol 2001; 19:2865-74.
Gabrilove JL, Cleeland C, Livingston RB, Sarokhan B, Winer E, Einhorn L. Clinical evaluation of once-weekly dosing of epoetin α in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001; 19:2875-82.
Case DC Jr, Bukowski RM, Carey RW, Fishkin EH, Henry DH, Jacobson RJ, et al. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 1993; 85:801-6.
Henry DH, Abels RI. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: Results of double-blind and open-label follow-up studies. Semin Oncol 1994; 21:21-8.
Pawlicki M, Jassem J, Bosze P, Lotan C, Kurteva GP, Siddiqui M, et al. A multicenter study of recombinant human erythropoietin (epoetin α) in the management of anemia in cancer patients receiving chemotherapy. Anticancer Drugs 1997; 8:949-57.
Abels RI. Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer. Semin Oncol 1992; 19:29-35.
Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S. Impact of therapy with epoetin α on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997; 15:1218-34.
Cazzola M, Messinger D, Battistel V, Bron D, Cimino R, Enller-Ziegler L, et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: Dose finding and identification of predictors of response. Blood 1995; 86:4446-53.
Osterborg A, Boogaerts MA, Cimino R, Essers U, Holowiecki J, Juliusson G, et al. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma - A randomized multicenter study. The European Study Group of Erythropoietin (Epoetin β) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma. Blood 1996; 87:2675-82.
Dunphy FR, Harrison BR, Dunleavy TL, Rodriguez JJ, Hilton JG, Boyd JH. Erythropoietin reduces anemia and transfusions: A randomized trial with or without erythropoietin during chemotherapy. Cancer 1999; 86:1362-7.
Ludwig H, Fritz E, Leitgeb C, Pecherstorfer M, Samonigg H, Schuster J. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 1994; 84:1056-63.
Cazzola M, Ponchio L, Beguin Y, Rosti V, Bergamaschi G, Liberato NL, et al. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial. Blood 1992; 79:29-37.
Cazzola M, Ponchio L, Pedrotti C, Farina G, Cerani P, Lucotti C, et al. Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy. Haematologica 1996; 81:434-41.
Ludwig H, Fritz E. Anemia of cancer patients: Patient selection and patient stratification for epoetin treatment. Semin Oncol 1998; 25:35-8.
Macdougall IC. Strategies for iron supplementation: Oral versus intravenous. Kidney Int Suppl 1 1999; 69:S61-6.
Danielson B. R-HuEPO hyporesponsiveness - Who and why? Nephrol Dial Transplant 1995; 10:69-73.
Biesma DH, Van de Wiel A, Beguin Y, Kraaijenhagen RJ, Marx JJ. Post-operative erythropoiesis is limited by the inflammatory effect of surgery on iron metabolism. Eur J Clin Invest 1995; 25:383-9.
Macdougall IC. Hyporesponsiveness to anemia therapy-what are we doing wrong? Perit Dial Int 2001; 21:S225-30.
Link H, Boogaerts MA, Fauser AA, Slavin S, Reiffers J, Gorin NC, et al. A controlled trial of recombinant human erythropoietin after bone marrow transplantation. Blood 1994; 84:3327-35.
Ludwig H, Fritz E, Leitgeb C, Krainer M, Kuhrer I, Sagaster P, et al. Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors. Ann Oncol 1993; 4:161-7.
Marsh WA, Rascati KL. Meta-analyses of the effectiveness of erythropoietin for end-stage renal disease and cancer. Clin Ther 1999; 21:1443-55.
Beguin Y, Loo M, R'Zik S, Sautois B, Lejeune F, Rorive G, et al. Early prediction of response to recombinant human erythropoietin in patients with the anemia of renal failure by serum transferrin receptor and fibrinogen. Blood 1993; 82:2010-6.
Henry DH, Abels R, Larholt K. Prediction of response to recombinant human erythropoietin (r-HuEPO/Epoietin-α) therapy in cancer patients. Blood 1995; 85:1676-8.
Cazzola M, Guarnone R, Cerani P, Centenara E, Rovati A, Beguin Y. Red blood cell precursor mass as an independent determinant of serum erythropoietin level. Blood 1998; 91:2139-45.
Carpenter MA, Kendall RG, O'Brien AE, Chapman C, Sebastian JP, Belfield PW, et al. Reduced erythropoietin response to anaemia in elderly patients with normocytic anaemia. Eur J Haematol 1992; 49:119-21.
Goodnough LT, Skikne B, Brugnara C. Erythropoietin, iron, and erythropoiesis. Blood 2000; 96:823-33.
Weinberg ED. The role of iron in cancer. Eur J Cancer Prev 1996; 5:19-36.
Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996; 50:1694-9.
Besarab A, Amin N, Ahsan M, Vogel SE, Zazuwa G, Frinak S, et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 2000; 11:530-8.
Sunder-Plassmann G, Horl WH. Safety aspects of parenteral iron in patients with end-stage renal disease. Drug Saf 1997; 17:241-50.
Drueke TB, Barany P, Cazzola M, Eschbach JW, Grutzmacher P, Kaltwasser JP, et al. Management of iron deficiency in renal anemia: Guidelines for the optimal therapeutic approach in erythropoietin-treated patients. Clin Nephrol 1997; 48:1-8.
Anonymous. Appendix III. Use of intravenous iron in patients receiving epoetin. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 1999; 14 Suppl 5:35-6.
Vreugdenhil G, Manger B, Nieuwenhuizen C, Feelders RA, van Eijk HG, Swaak AJ. Iron stores and serum transferrin receptor levels during recombinant human erythropoietin treatment of anemia in rheumatoid arthritis. Ann Hematol 1992; 65:265-8.
Martini A, Ravelli A, Di Fuccia G, Rosti V, Cazzola M, Barosi G. Intravenous iron therapy for severe anaemia in systemic-onset juvenile chronic arthritis. Lancet 1994; 344:1052-4.
Cazzola M, Coiffier B, Kloczko J, Spika I. Once weekly Neorecormon® (epoetin β) for the treatment of anemia associated with lymphoproliferative malignancies: Results of the NOW (Neorecormo® once weekly) study [abstract]. Hematol J 2002; 3 Suppl 1:64.
Glaspy J, Jadeja J, Justice G, et al. Darbepoetin α administered every 1 or 2 weeks (with no loss of dose efficiency) alleviates anemia in patients with solid tumors. Blood 2001; 98:298[abstract].
Glaspy J, Jadeja J, Justice G, Kessler J, Richards D, Tomita D, et al. Darbepoetin α administered every 1 or 2 weeks (with no loss of dose efficiency) alleviates anemia in patients with solid tumors. Hematol J 2002; 3 Suppl 1:67[abstract].
Glaspy J, Jadeja J, Justice G, Armstrong S, Colowick A, Tchekmedyian S, et al. Randomized, active-controlled, phase 1/2, dose-comparison study of NESP administered weekly or every 2 weeks in patients with solid tumors. Eur J Cancer 2001; 37:353 [abstract].
Hedenus M, Hansen S, Dewey C, Watson D, Colowick A, Osterborg A. A randomized, blinded, placebo-controlled, phase II, dose-finding study of NESP in patients with lymphoproliferative malignancies. Proc Am Soc Clin Oncol 2001; 20:393 [abstract].
Hedenus M, Glaspy J, Dewey C, O'Byrne J. Dose response of darbepoetin α is similar in anemic patients with solid tumors or lymphoproliferative malignancies. Blood 2001; 98:297 [abstract].
Pirker R, Vansteenkiste J, Gateley J, Yates P, Colowick A, Musil J. A phase III, double-blind, placebo-controlled, randomized study of novel erythropoiesis stimulating protein (NESP) in patients undergoing platinum-treatment for lung cancer. Eur J Cancer 2001; 37:264[abstract].
Smith R, Tchekmedyian NS, Richards D, et al. Darbepoetin α effectively alleviates anemia in patients with chronic anemia of cancer: Efficacy and pharmacokinetic results of a dose-escalation study. Proc Am Soc Clin Oncol 2002; 21:367[abstract].
Kotasek D, Albertsson M, Mackey J, Berg R, Robinson J, Colowick A. Randomized, double-blind, placebo-controlled, dose-finding study of darbepoetin α administered once every 3 (Q3W) or 4 (Q4W) weeks in patients with solid tumors. Proc Am Soc Clin Oncol 2002; 21:356[abstract].
Glaspy J, Jadeja J, Justice G, Fleishman A, Rossi G, Colowick A. Optimizing the management of anemia in patients with cancer: A randomized, active-controlled, study investigating the dosing of darbepoetin α. Hematol J 2002; 3 Suppl 1:67[abstract].